Holen Sie sich die Stockscreener-App
52.68
2.10%
-1.22
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$53.90
Offen:
$53.45
24-Stunden-Volumen:
835.63K
Relative Volume:
0.41
Marktkapitalisierung:
$7.87B
Einnahmen:
$1.17B
Nettoeinkommen (Verlust:
$150.71M
KGV:
56.04
EPS:
0.94
Netto-Cashflow:
$245.03M
1W Leistung:
+10.58%
1M Leistung:
+4.04%
6M Leistung:
-30.50%
1J Leistung:
-35.62%
1-Tages-Spanne:
$52.70
$53.66
1-Wochen-Bereich:
$46.77
$54.40
52-Wochen-Spanne:
$46.01
$85.57
Bio Techne Corp Stock (TECH) Company Profile
Firmenname
Bio Techne Corp
Sektor
Branche
Telefon
(612) 379-8854
Adresse
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Vergleichen Sie TECH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
52.70 | 7.87B | 1.17B | 150.71M | 245.03M | 0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.12 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.33 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
543.00 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.88 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
223.83 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-09 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-08 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-02-02 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-08-28 | Eingeleitet | William Blair | Outperform |
| 2023-01-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | Hochstufung | Stifel | Hold → Buy |
| 2021-01-25 | Bestätigt | The Benchmark Company | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-07-15 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | Herabstufung | Stifel | Buy → Hold |
| 2020-05-14 | Eingeleitet | The Benchmark Company | Buy |
| 2020-01-08 | Fortgesetzt | Stephens | Overweight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-02 | Hochstufung | Janney | Neutral → Buy |
| 2019-01-14 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | Herabstufung | Craig Hallum | Buy → Hold |
| 2018-10-17 | Eingeleitet | Goldman | Neutral |
| 2018-06-15 | Eingeleitet | Argus | Buy |
| 2017-07-13 | Eingeleitet | Wells Fargo | Market Perform |
| 2017-02-09 | Eingeleitet | Citigroup | Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Buy |
| 2016-11-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-01-21 | Bestätigt | Robert W. Baird | Outperform |
| 2013-09-20 | Hochstufung | Robert W. Baird | Neutral → Outperform |
Alle ansehen
Bio Techne Corp Aktie (TECH) Neueste Nachrichten
Waters Corporation, Avantor, Azenta, Bio-Techne, and Elanco Stocks Trade Up, What You Need To Know - Yahoo Finance
Bio-Techne to Showcase Next-Generation Solutions for Gene and Ce - GuruFocus
Bio-Techne to Showcase Next-Generation Solutions for Gene and Cell Therapy at American Society of Gene & Cell Therapy 2025 - Stock Titan
When the Price of (TECH) Talks, People Listen - news.stocktradersdaily.com
Bio-Techne (TECH) Target Price Lowered to $70 by UBS Analyst | T - GuruFocus
UBS Adjusts Price Target on Bio-Techne to $70 From $95, Maintains Buy Rating - marketscreener.com
Bio-Techne outlines 2025 growth drivers with NIH uncertainty and strong Protein Sciences performance - MSN
Beyond the Balance Sheet: What SWOT Reveals About Bio-Techne Corp (TECH) - GuruFocus
Bio-Techne, Kytopen collaborate on integrated cellular engineering workflow - TipRanks
Bio-Techne (TECH) Target Price Lowered by RBC Capital | TECH Sto - GuruFocus
Bio-Techne (TECH) Target Price Lowered by RBC Capital | TECH Stock News - GuruFocus
Benchmark Adjusts Bio-Techne Price Target to $75 From $95 - marketscreener.com
Bio-Techne (TECH): Benchmark Analyst Lowers Target Price but Maintains Buy Rating | TECH Stock News - GuruFocus
BIO-TECHNE (TECH): Analyst Maintains Hold Rating, Lowers Price Target | TECH Stock News - GuruFocus
Bio-Techne to Present at the BofA Securities 2025 Health Care Conference - StreetInsider
Kytopen and Bio-Techne Collaborate on an Integrated Cellular Eng - GuruFocus
Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing | TECH Stock News - GuruFocus
Bio-Techne price target lowered to $63 from $72 at RBC Capital - TipRanks
Kytopen and Bio-Techne Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing - Stock Titan
Bio-Techne Corporation (NASDAQ:TECH) Q3 2025 Earnings Call Transcript - Insider Monkey
Bio-Techne Third Quarter 2025 Earnings: EPS Misses Expectations - simplywall.st
Bio-Techne to Present at the BofA Securities 2025 Health Care Conference | TECH Stock News - GuruFocus
RBC Cuts Price Target on Bio-Techne to $63 From $72, Keeps Sector Perform Rating - marketscreener.com
Bio-Techne Corp (TECH) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amid Global ... - Yahoo Finance
Bio-Techne Corp (TECH) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amid Global Challenges - GuruFocus
Bio-Techne Reports Strong Q3 2025 Revenue Growth - TipRanks
Bio-Techne Q3 2025 Earnings Call Transcript - MarketBeat
Bio-Techne’s Earnings Call: Growth Amid Challenges - TipRanks
Revolutionizing Gene Therapy Protein Expression Potency Assays - Genetic Engineering and Biotechnology News
Bio-Techne Leads Key Proteomic Reagent Markets - Morningstar
Bio-Techne exceeds profit expectations, announces new share buyback plan - MSN
Bio-Techne reports Q3 adjusted EPS 56c, consensus 51c - TipRanks
Bio-Techne’s Resilience and Strong Financial Performance Justify Buy Rating Amid Market Challenges - TipRanks
Earnings call transcript: Bio-Techne beats Q3 2025 EPS forecasts, stock dips - Investing.com Nigeria
Evercore ISI Cuts Price Target on Bio-Techne to $60 From $70 - marketscreener.com
U.S. STOCKS ON THE MOVE-Bio-Techne, Johnson Controls, Tempus AI - TradingView
Bio-Techne Q3 Earnings & Revenues Top Estimates, Stock Up in Premarket - Zacks Investment Research
Bio Techne (TECH) Fell on Negative Funding Environment - Insider Monkey
Is the Options Market Predicting a Spike in BioTechne Stock? - Zacks Investment Research
Bio-Techne Shares Slide Amid Valuation Concerns - TipRanks
Bio-Techne Corporation Declares Dividend for the Quarter Ended March 31, 2025, Payable on May 30, 2025 - marketscreener.com
Bio-Techne shares surges nearly 6% on earnings beat, strong guidance - Investing.com Nigeria
Bio-Techne shares surges nearly 6% on earnings beat, strong guidance By Investing.com - Investing.com South Africa
BIO-TECHNE RELEASES THIRD QUARTER FISCAL 2025 RESULTS | TECH Sto - GuruFocus
Bio-Techne Board Approves Share Repurchase Program - Nasdaq
Bio-Techne Reports Q3 2025 Financial Results - TipRanks
Bio-Techne Corporation (TECH) Announces $500 Million Share Repurchase Program - GuruFocus
Bio-Techne Corp (TECH) Q3 Earnings: Adjusted EPS Surpasses Estimates at $0.56, Revenue Slightly Misses at $316.2 Million - GuruFocus
Bio-Techne earnings beat by $0.05, revenue fell short of estimates - Investing.com South Africa
BIO-TECHNE DECLARES DIVIDEND AND NEW SHARE REPURCHASE PROGRAM | TECH Stock News - GuruFocus
Bio-Techne (NASDAQ:TECH) Posts Q1 Sales In Line With Estimates, Stock Soars - Yahoo Finance
Finanzdaten der Bio Techne Corp-Aktie (TECH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bio Techne Corp-Aktie (TECH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bohnen Shane | SVP - General Counsel |
Apr 03 '25 |
Option Exercise |
0.00 |
2,260 |
0 |
3,941 |
| Herr Amy E. | Director |
Feb 14 '25 |
Option Exercise |
44.33 |
1,976 |
87,596 |
3,836 |
| Herr Amy E. | Director |
Feb 14 '25 |
Sale |
65.96 |
1,860 |
122,691 |
1,976 |
4.19%
0.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):